MedPath

Regenerative Potential of Cultured Gingival Fibroblast- Mesenchymal Stem Cells in Treatment of Periodontitis

Not Applicable
Completed
Conditions
Periodontal Intrabony Defect
Interventions
Procedure: β TCP bone substitute only
Procedure: GF+GMSCs carried on β TCP
Registration Number
NCT03638154
Lead Sponsor
Ain Shams University
Brief Summary

clinical trial was conducted to evaluate regenerative potentials of cultured gingival fibroblasts and GMSCs carried in beta tri calcium phosphate scaffold into intrabony periodontal defects in human by clinical and radiographic parameters

Detailed Description

In the present study, twenty posterior two or three osseous intrabony periodontal defects were involved . They were grouped in to two groups. Group I included ten intrabony posterior defect received beta tri calcium phosphate (β TCP) bone substitute. Group II included ten posterior intrabony periodontal defect and they received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of β TCP covered by a resorbable collagen membrane. CBCT was used preoperatively and after 6 months for hard tissue evaluation. PDGF and BMP were measured in GCF at days 1,3,7,14.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Presence of interproximal osseous defects estimated from radiographic evaluation (Cone Beam CT) and transgingival bone sounding ≥3mm of two or three osseous walls.

    • Probing Depth ≥5mm after initial therapy.
    • Attachment loss ≥4mm.
  • full mouth plaque score and bleeding on probing score ≤ 20% after phase I therapy.

    • non vital teeth only involved.
    • no furcation involvement of the teeth presenting the intraosseous defects.
    • Thick gingival biotype more than 1 mm with enough width of attached gingiva.
  • Accepts Healthy Volunteers

Read More
Exclusion Criteria
  • Patients with systemic disease or compromised immune illness using Cornell medical index
  • Smoker's patients.
  • Pregnant and lactating females.
  • Uncooperative patients (low compliance, bad oral hygiene).
  • Decision impaired individuals (prisoners, handicapped and mentally retarded patients).
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
GroupIβ TCP bone substitute onlysafety with received beta-tricalcium phosphate (β TCP) bone substitute only. (Bioresorb, Sybron, implant solutions GmbH Bremen, Germany)
GroupIIGF+GMSCs carried on β TCPsafety with surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane and received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of β TCP covered by a resorbable collagen membrane. (Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Jersey, USA).
Primary Outcome Measures
NameTimeMethod
bone gain in periodontal defects(by mm)6 months

20 patients were involved as assessed by cone beam ct at baseline (pre) and 6 months later(post). the fusion of pre and post operative cone beam ct scan of the intrabony periodontal defect to measure bone gain by mm. so that, the regenerative potentials of cultured gingival into ten intrabony defect fibroblasts and GMSCs carried by tri calcium phosphate , the bone gain was measured by radiographic fusion of pre and post image of intrabony periodontal defects in human.

Secondary Outcome Measures
NameTimeMethod
the regenerative power of the defect was evaluated by growth factor concentration in GCF.day 1,3,7,14 after surgery

4 GCF samples were collected from each patient at day 1,3,7,14 after periodontal surgery then a Biochemical analysis of BMP-2 and PDGF-bb (by mg /dl) concentrations in GCF by using ELIZA kite which reflect the healing power at the initial periods of healing in different groups.

© Copyright 2025. All Rights Reserved by MedPath